[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621405":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Bernardo Montesanti de Almeida, Medical","Hi Tecnologies","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Research Site","RECRUITING","Curitiba","Brazil","BR",{"type":27,"coordinates":28},"Point",[29,30],-49.27306,-25.42778,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100621405","observational-study-on-the-prevalence-and-risk-factors-of-patients-with-hyperkalaemia-in-brazil-100621405",false,"NCT07370194","Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil","Investigating the Impact of Serum Potassium Levels on Prevalence and Risk Factors Associated With Management Strategies for Patients With Hyperkalaemia in Brazilian Clinical Settings: An Observational Study.","HOPE","Inclusion Criteria:\n\n* Participants aged 18 years or older; Pre-existing comorbidities, including: o Heart failure (regardless of phenotype); o Chronic kidney disease (any stage); o Diabetes mellitus; o Systemic arterial hypertension.\n\nExclusion Criteria:\n\n* Diagnosis of advanced malignant neoplasm undergoing palliative treatment; Other advanced diseases with a life expectancy of less than one year; Patients with no information on risk factors for hyperkalaemia (HK).","ALL","18 Years",{"count":45,"type":46},6215,"ESTIMATED","OBSERVATIONAL","This is a descriptive, retrospective study involving patients from private cardiology, nephrology, and dialysis clinics in Brazil who participated in the National Hyperkalaemia Diagnosis Campaign. The study used anonymised data from the Hi Technologies Ltda. database. The objective was to estimate and characterise the prevalence of hyperkalaemia (HK), as well as to analyse the demographic profile, clinical characteristics, risk factors and treatment patterns associated with total blood potassium levels.",[50],"Hyperkalemia",[52],"serum potassium levels","2026-05-26",{"date":55,"type":56},"2026-05-27","ACTUAL",{"date":58,"type":56},"2026-03-31",{"date":60,"type":46},"2026-09-30",{"name":5,"class":6},1]